Abstract
While many novel therapies have been approved in recent years for treating patients with multiple myeloma, there is still no established curative regimen, especially for patients with high-risk disease. In this work, we use a mathematical modeling approach to determine combination therapy regimens that maximize healthy lifespan for patients with multiple myeloma. We start with a mathematical model for the underlying disease and immune dynamics, which was presented and analyzed previously. We add the effects of three therapies to the model: pomalidomide, dexamethasone, and elotuzumab. We consider multiple approaches to optimizing combinations of these therapies. We find that optimal control combined with approximation outperforms other methods, in that it can quickly produce a combination regimen that is clinically-feasible and near-optimal. Implications of this work can be used to optimize doses and advance the scheduling of drugs.
Original language | English |
---|---|
Article number | 106492 |
Journal | European Journal of Pharmaceutical Sciences |
Volume | 187 |
DOIs | |
State | Published - 1 Aug 2023 |
Keywords
- Combination drug regimen
- Constrained optimization
- Mathematical model
- Multiple myeloma
- Optimal control